medigraphic.com

2016, Number 4

<< Back Next >>

Rev Mex Anest 2016; 39 (4)

Construction of a nomogram to facilitate the calculation of equianalgesic doses for opioid rotation

Hernández-Ortiz A

Language: English
References: 66
Page: 251-260
PDF size: 242.58 Kb.


ABSTRACT

In order to make easier the process of dose calculation and to minimize dosage errors, a nomogram was developed, based on current recommendations for opioid dose calculation tools. Using Microsoft Excel 2013, a nomogram was created consisting of 18 parallel lines; some of them marked at 24 equidistant points as a minimum and most of them marked at 87 equidistant points as a maximum, resembling a ruler. The last mark of each line corresponds to the maximum recommended dose for each drug product or the dose equivalent. The nomogram developed for this document enables the equianalgesic dose calculation, at the same time that decreases the risk of making mathematical mistakes. Opioid rotation is an essential medical intervention when looking for efficacy and safety of opioid analgesics in clinical practice. Equianalgesic dose calculation is a complicated process with a high probability of error. The nomogram here described is a new tool able to reduce the complexity of calculation and to decrease the risk for the patient in terms of safety as well taking into account the available scientific evidence and following the measures recommended in the literature.


REFERENCES

  1. Vissers KC, Besse K, Hans G, Devulder J, Morlion B. Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract. 2010;10:85-93.

  2. Vadalouca A, Moka E, Argyra E, Sikioti, Siafaka I. Opioid rotation in patients with cancer: a review of current literature. J Opioid Manag. 2008;4:213-250.

  3. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38:426-439.

  4. Fine PG, Portenoy RK. Establishing “Best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38:418-425.

  5. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol. 2002;20:348-352.

  6. Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med. 2011;25:504-515.

  7. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids: A critical review and proposals for long-term dosing. J Pain Symptom Manage. 2001;22:672-687.

  8. Webster LR, Fine PG. Overdose deaths demand a new paradigm for opioid rotation. Pain Med. 2012;13:571-574.

  9. Cherny NJ, Chang V, Frager G, Ingham JM, Tiseo PJ, Popp B, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995;76:1283-1293.

  10. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004;3:CD004847.

  11. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al; Americal Pain Society. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231-256.

  12. Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med. 2011;25:494-503.

  13. Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med. 2012;13:562-570.

  14. McPherson ML. Demystifying opioid conversion calculations. American Society of Health System Pharmacists, Bethesda MD, 2010.

  15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain. Available from: External link http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive

  16. Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin. 2009;25:2133-2150.

  17. Borgsteede SD, Rhodius CA, De Smet PA, Pasman HR, Onwuteaka-Philipsen BD, Rurup ML. The use of opioids at the end of life: knowledge level of pharmacists and cooperation with physicians. Eur J Clin Pharmacol. 2011;67:79-89.

  18. Plagge H, Ruppen W, Ott N, Fabbro T, Bornand D, Deuster S. Dose calculation in opioid rotation: Electronic calculator vs manual calculation. Int J Clin Pharm. 2011;33:25-32.

  19. Passik SD. Opioid rotation: what is the rush? Pain Med. 2012;13:487-488.

  20. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther. 1990;4:639-646.

  21. Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, et al; Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587-593.

  22. Eastern Metropolitan Region Palliative Care Consortium (Victoria) Clinical Group. Opioid Conversion Ratios-Guide to Practice 2010 (November 2014). Available from: External link http://www.emrpcc.org .au/wp-content/uploads/2013/03/EMRPCC-Opioid-Conversion2010-Final2.pdf Accessed December 29th, 2015.

  23. Eastern Metropolitan Region Palliative Care Consortium (Victoria) Clinical Group. Opioid Conversion Ratios-Guide to Practice 2013 v 2 (November 2014). Available from: External link http://www.emrpcc.org.au/wp-content/uploads/2014/12/EMRPCC-OpioidConversion-2013-V2-November-2014.pdf Accessed December 29th, 2015.

  24. Stuart-Harris R, Joel SP, McDonald P, Currow D, Slevin ML. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusions of morphine. Br J Clin Pharmacol. 2000;49:207-214.

  25. Glare PA, Walsh TD. Dose-ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol. 1993;11:973-978.

  26. Curtis GB, Johnson GH, Clark P, Taylor R, Brown J, O’Callaghan R, et al. Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol. 1999;55:425-429.

  27. Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, et al. Randomized, double-blind, crossover trial comparing safety and efficacy of oral controlled-release oxycodone with controlled release morphine in patients with cancer pain. J Clin Oncol. 1998;16:3222-3229.

  28. Gippsland Region Palliative Care Consortium Clinical Practice Group. Opioid Conversion Guidelines (August 2013). Available from: External link http://www.grpcc.com.au/wp-content/uploads/2014/01/GRPCC-CPG002_1.0_2011-Opioid-Conversion-Guidelines.pdf Accessed December 29th, 2015.

  29. Pöyhiä R, Seppälä T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992;33:617-621.

  30. Paix A, Coleman A, Lees J, Grigson J, Brooksbank M, Thorne D. Subcutaneous fentanyl and sufentanyl infusion substitution for morphine intolerance in cancer pain management. Pain. 1995;63:263-269.

  31. Hunt R, Fazekas B, Thorne D, Brooksbank M. A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manage. 1999;18:111-119.

  32. Prommer E. The role of fentanyl in cancer-related pain. J Palliat Med. 2009;12:947-954.

  33. Zech DF, Grond SU, Lynch J, Dauer HG, Stollenwerk B, Lehmann KA. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain. 1992;50:293-301.

  34. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32:304-315.

  35. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996;64:527-534.

  36. Mercadante S, Porzio G, Fulfaro F, Aielli F, Verna L, Ficorella C, et al. Switching from transdermal drugs: an observational “N of 1” study of fentanyl and buprenorphine. J Pain Symptom Manage. 2007;34:532-538.

  37. Mercadante S, Casuccio A, Tirelli W, Giarratano A. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Canc. 2009;17:715-718.

  38. Breitbart W, Chandier S, Eagel B, Ellison N, Enck RE, Lefkowitz M, et al. An alternative algorithm for dosing transdermal fentanyl for cancer related pain. Oncology. 2000;14:695-705.

  39. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain: a retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer. 1996;78:852-857.

  40. Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT Jr, Dornseif BE, et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage. 2002;23:355-368.

  41. Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain. 1997;72:79-85.

  42. Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC. Conversion from standard opioid therapy to opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. J Int Med Res. 2008;36:343-352.

  43. Torres MLM. Tapentadol retard en el dolor crónico intenso. Rev Soc Esp Dolor. 2011;18:283-290.

  44. Mercadante S, Porzio G, Ferrera P, Aielli F, Adile C, Ficorella C, et al. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin. 2012;28:1775-1779.

  45. Tzschentke TM, De Vry J, Terliden R. Tapentadol hydrochioride: analgesic mu-opioid receptor agonist noradrenaline reuptake inhibitor. Drugs Future. 2006;31:1053-1061.

  46. Gálvez R, Schäfer M, Hans G, Faike D, Steigerwald I. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label phase 3b study. Adv Ther. 2013;30:229-259.

  47. Mercadante S, Porzio G, Aielli F, Adile C, Verna L, Ficorella C, et al. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin. 2013;29:661-666.

  48. Davis MP. Buprenorphine in cancer pain. Support Care Cancer. 2005;13:878-887.

  49. Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10:209-219.

  50. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10:428-450.

  51. Likar R. Transdermal buprenorphine in the management of persistent pain-safety aspects. Ther Clin Risk Manag. 2006;2:115-125.

  52. Louis F. Transdermal buprenorphine in pain management-experiences from clinical practice: Five case studies. Int J Clin Pract. 2006;60:1330-1334.

  53. Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther. 2005;27:225-237.

  54. Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med. 2006;20:S25-S30.

  55. Kjaer M, Henriksen H, Knudsen J. A comparative study of intramuscular buprenorphine and morphine in the treatment of chronic pain of malignant origin. Br J Clin Pharmacol. 1982;13:487-492.

  56. Zacny JP, Conley K, Galinkin J. Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J Pharm Exp Ther. 1997;282:1187-1197.

  57. Bullingham RE, McQuay HJ, Dwyer D, Allen MC, Moore RA. Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol. 1981;12:117-122.

  58. Silvasti M, Svartling N, Pitkänen M, Rosenberg PH. Comparison of intravenous patientcontrolled analgesia with tramadol versus morphine after microvascular breast reconstruction. Eur J Anaesthesiol. 2000;17:448-455.

  59. Wilder-Smith CH, Hill L, Wilkins J, Denny L. Effects of morphine and tramadol on somatic and visceral sensory function and gastrointestinal motility after abdominal surgery. Anesthesiology. 1999;91:639-647.

  60. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;31:879-923.

  61. Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage. 1999;18:174-179.

  62. Wilder-Smith CH, Schimike J, Osterwalder B, Senn HJ. Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol. 1994;5:141-146.

  63. Burget DE Jr, Greene NM. Dextro propoxyphene and the ventilatory response to carbon dioxide in man. Yale J Biol Med. 1962;35:185-188.

  64. Gruber CM Jr. Codeine phosphate, propoxyphene hydrochioride, and placebo. J An Med Assoc. 1957;164:966-969.

  65. Divvela S, Williams A, Meives C, Gozun E. Opioid analgesics: comparison of pharmacokinetics and equianalgesic doses. Hospital Pharm. 2006;42:1130-1135.

  66. Twycross R, Wilcock A. Symptom management in advanced cancer. Radcliffe Medical Press, Third Edition, UK, 1997.




2020     |     www.medigraphic.com